A new drug shortage is drawing attention from dental sedation providers. According to an October 1 ADA News report, dentists may have trouble accessing flumazenil because of an ongoing shortage, a drug that is used to reverse overdosages in oral sedation situations with benzodiazepines, and some state laws may require it to be on hand when performing these procedures. For practices that offer minimal, moderate, or IV sedation, this is worth flagging now rather than discovering it mid-appointment.
What's Actually Short
The affected products include flumazenil injections manufactured by Baxter, Fresenius Kabi and Hikma, according to a Sept. 21 drug shortage bulletin from the University of Utah Drug Information Service and American Society of Health-System Pharmacists. The situation varies by manufacturer and vial size:
- Baxter has reported its 5- and 10-milliliter vials are on back order, and the company cannot estimate when they will be available again.
- Fresenius Kabi's 5- and 10-milliliter vials are also on back order, with estimated release dates of mid-October for the 5-milliliter vials and early October for the 10-milliliter vials.
- Hikma has 10-milliliter vials on back order as well and estimates they will be released in mid- to late October. Notably, Hikma's flumazenil injection in a 5-milliliter vial was still available as of Sept. 21.
So availability isn't zero β but it's inconsistent, and practices relying on a single distributor or manufacturer could find themselves without a reliable source heading into the fall and winter procedure season.
Why This Matters for Compliance, Not Just Convenience
Flumazenil isn't a nice-to-have. In many states, it's a documented requirement for any practice administering benzodiazepine-based sedation, whether that's a single oral dose for an anxious patient or deeper moderate/IV sedation during oral surgery. State dental boards that issue sedation permits generally expect reversal agents β flumazenil for benzodiazepines, naloxone for narcotics β to be physically on hand and within date as a condition of the permit, not just a best practice. A shortage doesn't suspend that requirement; it just makes meeting it harder.
What Practices Should Do Now
- Audit current stock. Check expiration dates and quantities on hand today, not when the next sedation case is scheduled.
- Call your distributor directly. Ask about current allocation, expected restock windows, and whether an alternate manufacturer's vial size is available even if your usual one isn't.
- Don't assume interchangeability without checking your protocol. A 5 mL vial from one manufacturer may carry a different concentration or labeling than what your emergency kit checklist specifies β update kit documentation if you substitute.
- Review your state's sedation permit requirements. If your board requires proof of reversal agents on file, know what documentation you'd need to show if an inspection coincides with a stock gap.
- Loop in whoever manages your emergency drug kit. This is a good moment to confirm all reversal and emergency medications are current, not just flumazenil.
The Bigger Pattern
This shortage is a reminder that sedation-related pharmaceuticals, unlike many consumable dental supplies, often come from a small number of manufacturers with limited substitution options. Practices that build a secondary supplier relationship before a shortage hits are in a much better position than those scrambling once a case is already on the schedule. Keep an eye on ADA and ASHP shortage bulletins through the rest of the year, as manufacturers' own restock estimates have already shifted once since the initial September report.